- The folks at University of Southern California are studying the effects of laboratory biomarker analysis; pharmacological study; questionnaire administration; fluorine F 18-clevudine; positron emission tomography/computed tomography on Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Stage II Breast Cancer, Stage IB Breast Cancer, Stage IA Breast Cancer, Recurrent Breast Cancer, HER2-positive Breast Cancer, Stage IIIC Breast Cancer and Stage IV Breast Cancer in females ages 18 years and older. This clinical trial is slated to start October 2012 and is expected to end circa October 2015.
This study is officially titled, "Development of an In Vivo Cell Proliferation Marker for PET Assessment of Chemotherapeutic Response in Cancer."
|Recruiting||USC Norris Comprehensive Cancer Center|
Los Angeles, California, 90033
United States - map
For more study details, please visit this link to ClinicalTrials.gov record, which is the source of this webpage.